ATG’s primary responsibility is the production of radiopharmaceuticals for commercial use; however, the team also supports nuclear medicine research at the lab by producing the radioisotopes and contributed to the construction of the first TRIUMF PET scanner in 1981.

In the time since, ATG has operated as many as three compact cyclotrons for the production of medical isotopes. The team now consists of over 30 operators, engineers, technicians and managers, all of whom are TRIUMF employees working in partnership with BWXT Inc, a United States based, commercial company.

See featured media to explore the Division Spotlight movie and 360 cyclotron imagery.

This group continues to innovate on the design and operation of compact cyclotrons. This has become a key element in the symbiotic relationship between TRIUMF and medicine. Every week, the team helps to deliver over 35,000 patient doses of medical isotopes for BWXT, which are then distributed for patient care to facilities around the world.

ATG also maintains the Solid Target Facility (STF) and the Isotope Production Facility (IPF) both connected to the main cyclotron. The team collaborates with groups across the lab, providing support through their expertise in designing setups and systems for use in high contamination and high radiation areas – systems that are resilient, modular, and easy to maintain – like those being used in IAMI for the latest TR-24 cyclotron.